NEW YORK — T2 Biosystems said Friday that one of its European patents covering a direct-from-whole-blood pathogen detection method has been upheld by the European Patent Office.
The patent — European Patent No. 3,443,124 — claims methods, systems, and cartridges for the amplification of target nucleic acids in complex samples including whole blood. It also claims diagnostic and therapeutic methods based on this amplification.
According to T2 Bio, French diagnostics maker BioMérieux and other undisclosed firms had filed an opposition to the patent in May 2023. The Lexington, Massachusetts-based company said that the European Patent Office upheld the intellectual property on Thursday.